MSI-H mCRC | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

9,824 results for “MSI-H mCRC”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

66 participants · First posted Nov 24, 2025

Not yet recruiting

A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)

88 participants · First posted Sep 8, 2026

Active, not recruiting

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

839 participants · First posted Jul 5, 2019

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

671 participants · First posted Jul 22, 2020

Active, not recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

453 participants · First posted Jun 6, 2023

KN035 for dMMR/MSI-H Advanced Solid Tumors

200 participants · First posted Sep 12, 2018

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

24 participants · First posted Aug 16, 2023

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

30 participants · First posted Apr 5, 2022

Not yet recruiting

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

22 participants · First posted Jun 6, 2025

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

50 participants · First posted Apr 18, 2023

Page 1 of 736